Editas Medicine (EDIT) Free Cash Flow (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Free Cash Flow data on file, last reported at -$30.8 million in Q3 2025.

• On a quarterly basis, Free Cash Flow rose 41.99% year-over-year to -$30.8 million in Q3 2025; TTM through Dec 2025 was -$128.9 million, a 37.73% increase from a year earlier, with the FY2024 full-year figure at -$206.9 million, down 52.69% from the prior year.
• Free Cash Flow for Q3 2025 stood at -$30.8 million, up from -$51.2 million in the prior quarter.
• Over the last five years, Free Cash Flow for EDIT reached as high as -$22.2 million in Q4 2023 and fell as low as -$55.7 million in Q2 2024.
• Historically, Free Cash Flow has averaged -$42.8 million across 5 years, with a median of -$41.3 million in 2021.
• Across the five-year window, Free Cash Flow soared 45.01% in 2023 and plunged 113.25% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at -$34.6 million in 2021, then decreased by 16.44% to -$40.3 million in 2022, then jumped by 45.01% to -$22.2 million in 2023, then plunged by 113.25% to -$47.3 million in 2024, then jumped by 34.74% to -$30.8 million in 2025.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$30.8 million in Q3 2025, -$51.2 million in Q2 2025, and -$46.8 million in Q1 2025.